Search
Merck Eyes Acquisition of U.S. Cancer and Rare Disease Drugmaker SpringWorks
2025-02-11 /
Read about 0 minute
Author：小编
On February 10, Reuters reported that global pharmaceutical giant Merck is in advanced discussions with SpringWorks Therapeutics, a U.S.-based company specializing in cancer and rare disease treatments. An acquisition agreement is anticipated to be finalized within the coming weeks. SpringWorks, which boasts a market value of roughly $3.4 billion, is poised to become part of Merck's portfolio. This strategic move will not only fortify Merck's position in the biopharmaceutical sector but is also expected to bolster its research and development capabilities in the fields of cancer and rare disease medications.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
